Non-Urological Cancers Affecting the Urinary Tract
Cervix (%risk nodal metastases) Cervix (%risk nodal metastases) IA Microscopic disease confined to the cervix IA1 1 – ≤3 mm deep, ≤7 mm wide (<2 %) IA2 2 – 3–5…
Cervix (%risk nodal metastases) Cervix (%risk nodal metastases) IA Microscopic disease confined to the cervix IA1 1 – ≤3 mm deep, ≤7 mm wide (<2 %) IA2 2 – 3–5…
Fig. 15.1 Appropriate care near the end of life (Adapted from Lynn and Adamson [34]. With permission from RAND Corporation) Recently published research in patients with metastatic non-small cell lung…
T – Primary tumor TX Primary tumor cannot be assessed TO No evidence of primary tumor Tis Carcinoma in situ Ta Noninvasive verrucous carcinoma TI Tumor invades subepithelial connective tissue…
Parameter Raghavan et al. [16] Tannock et al. [14] Kantoff et al. [17] Ernst et al. [18] Berry et al. [19] Raghavan et al. [20] Age Median 64 69 72…
© Springer-Verlag London 2015Vinod H. Nargund, Derek Raghavan and Howard M. Sandler (eds.)Urological Oncology10.1007/978-0-85729-482-1_47 47. Management of Locally Advanced Prostate Cancer Elaine T. Lam1 and L. Michael Glodé1 (1) Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora,…
1. Patients with previous abdominal/pelvic surgery 2. High body mass index 3. Previous prostatic surgery 4. Kidney transplantation/mesh abdominal repair The proponents of RPP describe it as procedure that provides…
Risk group Combination of pretreatment variables Low ≤T2a and PSA ≤10 ng/ml and GS ≤6 Intermediate T2b or PSA 10.1–20 ng/ml or GS = 7 High ≥T2c or PSA >20 ng/ml or…
© Springer-Verlag London 2015Vinod H. Nargund, Derek Raghavan and Howard M. Sandler (eds.)Urological Oncology10.1007/978-0-85729-482-1_41 41. Expectant Management of Localized Prostate Cancer Maria Carmen Mir1 and Andrew J. Stephenson2 (1) Department of Urology, Cleveland Clinic, Cleveland, OH, USA (2) Glickman Urological…
The BED normally carries a subscript corresponding to the assumed α/β since it is clearly different for large and small α/β. Thus, for any given fractionation schedule, one must determine…
Fig. 3.1 Clonal evolution drives tumor progression. (a) Healthy epithelium. (b) The first oncogenic mutation occurs in a single epithelium cell (Yellow cell) resulting in the growth of a genetically…